PriceTargets.com logo

Charles River Laboratories International - CRL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $174.54
  • Forecasted Upside: 10.17%
  • Number of Analysts: 16
  • Breakdown:
  • 1 Sell Ratings
  • 10 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$158.43 As of 07/14/2025 12:49 PM ET
▼ -0.974 (-0.61%)

This chart shows the closing price for CRL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Charles River Laboratories International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRL

Analyst Price Target is $174.54
▲ +10.17% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Charles River Laboratories International in the last 3 months. The average price target is $174.54, with a high forecast of $210.00 and a low forecast of $140.00. The average price target represents a 10.17% upside from the last price of $158.43.

This chart shows the closing price for CRL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 16 investment analysts is to hold stock in Charles River Laboratories International. This rating has held steady since April 2025, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 2 sell ratings
Ratings as of
10/17/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 3 sell ratings
Ratings as of
1/15/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 15 hold ratings
  • 1 sell ratings
Ratings as of
4/15/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 12 hold ratings
  • 1 sell ratings
Ratings as of
6/14/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
7/14/2025

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 10 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/9/2025Evercore ISIBoost TargetOutperform ➝ Outperform$170.00 ➝ $180.00
7/9/2025CitigroupUpgradeNeutral ➝ Buy$150.00 ➝ $200.00
5/23/2025Redburn AtlanticUpgradeNeutral ➝ Buy$188.00 ➝ $182.00
5/14/2025CowenUpgradeHold ➝ Buy
5/14/2025TD CowenUpgradeHold ➝ Buy$179.00
5/8/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$145.00 ➝ $155.00
5/8/2025Robert W. BairdBoost TargetNeutral ➝ Neutral$118.00 ➝ $140.00
5/8/2025Evercore ISIUpgradeIn-Line ➝ Outperform$170.00
4/10/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$160.00 ➝ $145.00
4/9/2025MizuhoLower TargetNeutral ➝ Neutral$175.00 ➝ $155.00
3/21/2025The Goldman Sachs GroupDowngradeBuy ➝ Neutral$190.00 ➝ $170.00
3/4/2025CitigroupUpgradeSell ➝ Neutral$155.00 ➝ $175.00
3/3/2025Redburn AtlanticUpgradeSell ➝ Neutral$188.00
2/20/2025JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$175.00 ➝ $165.00
2/20/2025Robert W. BairdLower TargetNeutral ➝ Neutral$177.00 ➝ $173.00
2/18/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$205.00 ➝ $166.00
2/5/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$220.00 ➝ $184.00
2/3/2025JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$215.00 ➝ $175.00
1/23/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$220.00 ➝ $190.00
1/22/2025William BlairDowngradeOutperform ➝ Market Perform
1/17/2025UBS GroupReiterated RatingBuy ➝ Neutral$250.00 ➝ $185.00
1/14/2025William BlairReiterated RatingOutperform ➝ Outperform
12/13/2024Bank of AmericaLower TargetNeutral ➝ Neutral$220.00 ➝ $210.00
11/18/2024CLSADowngradeHold ➝ Underperform$164.00
11/11/2024TD CowenBoost TargetHold ➝ Hold$203.00 ➝ $227.00
11/7/2024UBS GroupBoost TargetBuy ➝ Buy$240.00 ➝ $250.00
11/7/2024CLSAUpgradeUnderperform ➝ Hold$205.00
11/7/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$190.00 ➝ $225.00
10/23/2024CLSAInitiated CoverageUnderperform$167.00
10/14/2024Redburn AtlanticInitiated CoverageSell$151.00
10/7/2024Evercore ISIDowngradeOutperform ➝ Inline$225.00 ➝ $190.00
10/2/2024Bank of AmericaDowngradeBuy ➝ Neutral$250.00 ➝ $215.00
10/1/2024CitigroupDowngradeNeutral ➝ Sell$215.00 ➝ $175.00
9/20/2024Robert W. BairdLower TargetNeutral ➝ Neutral$191.00 ➝ $190.00
8/12/2024TD CowenLower TargetHold ➝ Hold$228.00 ➝ $203.00
8/8/2024Baird R WDowngradeStrong-Buy ➝ Hold
8/8/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$230.00 ➝ $210.00
8/8/2024UBS GroupLower TargetBuy ➝ Buy$290.00 ➝ $240.00
8/8/2024Evercore ISILower TargetOutperform ➝ Outperform$265.00 ➝ $225.00
8/8/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$290.00 ➝ $250.00
8/8/2024Robert W. BairdDowngradeOutperform ➝ Neutral$239.00 ➝ $191.00
8/8/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$270.00 ➝ $205.00
7/10/2024Robert W. BairdLower TargetOutperform ➝ Outperform$271.00 ➝ $239.00
6/28/2024BarclaysInitiated CoverageEqual Weight$230.00
6/28/2024ArgusReiterated RatingBuy ➝ Hold
6/7/2024MizuhoInitiated CoverageNeutral$235.00
6/6/2024The Goldman Sachs GroupInitiated CoverageBuy$290.00
5/13/2024TD CowenLower TargetHold ➝ Hold$260.00 ➝ $228.00
5/10/2024Robert W. BairdLower TargetOutperform ➝ Outperform$282.00 ➝ $270.00
3/18/2024ArgusBoost TargetBuy ➝ Buy$240.00 ➝ $290.00
2/15/2024Evercore ISIBoost TargetOutperform ➝ Outperform$260.00 ➝ $265.00
2/15/2024CitigroupBoost TargetNeutral ➝ Neutral$215.00 ➝ $250.00
2/15/2024UBS GroupBoost TargetBuy ➝ Buy$270.00 ➝ $290.00
2/15/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$270.00 ➝ $280.00
2/15/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$252.00 ➝ $268.00
2/15/2024GuggenheimDowngradeBuy ➝ Neutral
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$210.00 ➝ $270.00
12/11/2023CitigroupBoost TargetNeutral ➝ Neutral$190.00 ➝ $215.00
11/10/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$220.00 ➝ $205.00
11/9/2023UBS GroupLower TargetBuy ➝ Buy$250.00 ➝ $215.00
10/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$235.00 ➝ $220.00
10/11/2023Evercore ISILower Target$235.00 ➝ $225.00
9/25/2023TD CowenLower TargetMarket Perform ➝ Market Perform$212.00 ➝ $209.00
9/22/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$280.00 ➝ $275.00
9/22/2023GuggenheimLower TargetBuy ➝ Buy$255.00 ➝ $225.00
9/22/2023Robert W. BairdLower TargetOutperform ➝ Outperform$267.00 ➝ $256.00
9/22/2023Bank of AmericaLower Target$245.00 ➝ $230.00
9/13/2023TD CowenInitiated CoverageMarket Perform$212.00
8/10/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$225.00 ➝ $250.00
8/10/2023Bank of AmericaBoost TargetBuy ➝ Buy$235.00 ➝ $245.00
7/10/2023CitigroupDowngradeBuy ➝ Neutral$260.00 ➝ $225.00
5/12/2023Deutsche Bank AktiengesellschaftLower Target$260.00 ➝ $250.00
5/12/2023Wells Fargo & CompanyLower Target$290.00 ➝ $280.00
5/12/2023Credit Suisse GroupLower Target$260.00 ➝ $255.00
3/28/2023Jefferies Financial GroupLower TargetHold$233.00 ➝ $203.00
2/23/2023Morgan StanleyLower TargetEqual Weight$241.00 ➝ $230.00
2/23/2023Credit Suisse GroupLower TargetOutperform$280.00 ➝ $260.00
2/23/2023CitigroupLower TargetBuy$280.00 ➝ $260.00
2/23/2023GuggenheimUpgradeNeutral ➝ Buy$255.00
1/12/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
1/11/2023Robert W. BairdBoost TargetOutperform$275.00 ➝ $285.00
11/3/2022JPMorgan Chase & Co.Lower TargetOverweight$280.00 ➝ $275.00
11/3/2022Morgan StanleyLower TargetEqual Weight$250.00 ➝ $241.00
11/3/2022Credit Suisse GroupLower TargetOutperform$285.00 ➝ $280.00
11/2/2022William BlairReiterated RatingOutperform
9/29/2022Jefferies Financial GroupUpgradeHold ➝ Buy$240.00
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$285.00
8/16/2022Wells Fargo & CompanyLower TargetOverweight$325.00 ➝ $300.00
8/9/2022Evercore ISILower Target$260.00
8/9/2022CitigroupLower Target$280.00
8/8/2022Deutsche Bank AktiengesellschaftLower Target$290.00 ➝ $270.00
8/4/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$350.00 ➝ $250.00
7/14/2022Deutsche Bank AktiengesellschaftLower TargetBuy$350.00 ➝ $290.00
6/20/2022StephensSet Target$315.00
5/23/2022GuggenheimInitiated CoverageNeutral
5/5/2022KeyCorpLower Target$390.00 ➝ $300.00
4/25/2022Wells Fargo & CompanyLower TargetOverweight$390.00 ➝ $325.00
4/25/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$370.00 ➝ $280.00
4/6/2022StephensInitiated CoverageOverweight$377.00
2/17/2022Bank of AmericaLower TargetBuy$445.00 ➝ $400.00
2/17/2022UBS GroupLower TargetBuy$465.00 ➝ $420.00
2/17/2022Morgan StanleyLower TargetOverweight$465.00 ➝ $430.00
2/17/2022Wells Fargo & CompanyLower Target$450.00 ➝ $390.00
2/17/2022Deutsche Bank AktiengesellschaftLower TargetBuy$409.00 ➝ $350.00
2/17/2022CitigroupUpgradeNeutral ➝ Buy$400.00
2/17/2022KeyCorpLower TargetOverweight$450.00 ➝ $390.00
12/20/2021Robert W. BairdReiterated RatingBuy
11/16/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$354.00 ➝ $409.00
11/12/2021Robert W. BairdReiterated RatingBuy$452.00
11/4/2021Morgan StanleyLower TargetOverweight$480.00 ➝ $465.00
11/4/2021CitigroupLower TargetNeutral$425.00 ➝ $400.00
10/14/2021Evercore ISIReiterated RatingBuy
8/23/2021ArgusBoost TargetBuy$390.00 ➝ $480.00
8/17/2021UBS GroupBoost TargetBuy$390.00 ➝ $465.00
8/5/2021Credit Suisse GroupBoost TargetNeutral$385.00 ➝ $420.00
8/5/2021Wells Fargo & CompanyBoost TargetOverweight$375.00 ➝ $470.00
8/5/2021Robert W. BairdBoost TargetOutperform$410.00 ➝ $461.00
7/20/2021Credit Suisse GroupBoost TargetNeutral$352.00 ➝ $385.00
5/31/2021Robert W. BairdReiterated RatingBuy
5/28/2021Credit Suisse GroupBoost TargetNeutral$342.00 ➝ $352.00
5/28/2021JPMorgan Chase & Co.Boost TargetPositive ➝ Overweight$375.00 ➝ $390.00
5/28/2021CitigroupBoost TargetNeutral$350.00 ➝ $355.00
5/25/2021Truist FinancialBoost TargetBuy$324.00 ➝ $369.00
5/14/2021KeyCorpBoost TargetOverweight$340.00 ➝ $360.00
5/5/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$334.00 ➝ $354.00
5/5/2021Robert W. BairdBoost TargetOutperform$338.00 ➝ $400.00
2/25/2021Morgan StanleyBoost TargetOverweight$280.00 ➝ $350.00
2/18/2021Truist FinancialBoost Target$256.00 ➝ $324.00
2/18/2021Credit Suisse GroupBoost TargetNeutral$259.00 ➝ $301.00
2/18/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$250.00 ➝ $334.00
12/22/2020ArgusBoost TargetBuy$235.00 ➝ $265.00
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral
11/24/2020KeyCorpBoost TargetOverweight$233.00 ➝ $256.00
11/3/2020Truist FinancialBoost Target$237.00 ➝ $256.00
10/30/2020Morgan StanleyBoost TargetOverweight$245.00 ➝ $260.00
10/30/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$235.00 ➝ $250.00
9/14/2020ArgusBoost TargetBuy$190.00 ➝ $235.00
9/10/2020Jefferies Financial GroupUpgradeHold ➝ Buy$213.00 ➝ $254.00
8/18/2020KeyCorpBoost TargetOverweight$186.00 ➝ $233.00
8/6/2020Morgan StanleyBoost TargetOverweight$175.00 ➝ $245.00
8/6/2020CitigroupBoost TargetBuy$190.00 ➝ $255.00
7/21/2020UBS GroupBoost TargetBuy$200.00 ➝ $236.00
(Data available from 7/14/2020 forward)

News Sentiment Rating

1.22 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 40 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/16/2024
  • 7 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/15/2025
  • 27 very positive mentions
  • 20 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Mentions as of
2/14/2025
  • 61 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/16/2025
  • 64 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
4/15/2025
  • 55 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
5/15/2025
  • 51 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/14/2025
  • 26 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/14/2025

Current Sentiment

  • 26 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Charles River Laboratories International logo
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $158.43
Low: $155.48
High: $160.41

50 Day Range

MA: $144.87
Low: $115.21
High: $163.63

52 Week Range

Now: $158.43
Low: $91.86
High: $254.15

Volume

184,789 shs

Average Volume

1,030,754 shs

Market Capitalization

$7.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Charles River Laboratories International?

The following sell-side analysts have issued research reports on Charles River Laboratories International in the last year: Baird R W, Bank of America Corporation, Barclays PLC, Citigroup Inc., CLSA, Cowen Inc, Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Redburn Atlantic, Robert W. Baird, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, and William Blair.
View the latest analyst ratings for CRL.

What is the current price target for Charles River Laboratories International?

0 Wall Street analysts have set twelve-month price targets for Charles River Laboratories International in the last year. Their average twelve-month price target is $174.54, suggesting a possible upside of 10.2%. Bank of America Corporation has the highest price target set, predicting CRL will reach $210.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $140.00 for Charles River Laboratories International in the next year.
View the latest price targets for CRL.

What is the current consensus analyst rating for Charles River Laboratories International?

Charles River Laboratories International currently has 1 sell rating, 10 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRL, but not buy more shares or sell existing shares.
View the latest ratings for CRL.

What other companies compete with Charles River Laboratories International?

Other companies that are similar to Charles River Laboratories International include Icon, Bio-Techne, IQVIA, Mettler-Toledo International and Waters. Learn More about companies similar to Charles River Laboratories International.

How do I contact Charles River Laboratories International's investor relations team?

Charles River Laboratories International's physical mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company's listed phone number is (781) 222-6000 and its investor relations email address is [email protected]. The official website for Charles River Laboratories International is www.criver.com. Learn More about contacing Charles River Laboratories International investor relations.